Immunis, Inc.
June 16, 2025
Company Presentation
Regenerative Medicine
Immunis is a clinical-stage biotech developing multi-active biologics to address age-related diseases and immune dysregulation. Metabolic and immune health decline with age, commonly manifesting as muscle atrophy (sarcopenia), obesity, and reduced physical function. Our investigational IMM01-STEM therapy contains all-natural bioactive molecules published in aged mouse models to improve muscle mass and strength, enhance immune cell recruitment, increase lean mass, reduce fat mass, and increase physical activity. Immunis completed a Phase 1/2a clinical trial testing the safety, tolerability, and efficacy of IMM01-STEM in sarcopenic individuals with knee osteoarthritis and is conducting a Phase 2 placebo-controlled study in adults with sarcopenic obesity.
Company HQ City:
Irvine
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2019
Lead Product in Development:
IMM01-STEM, a stem cell-derived multi-active biologic
CEO
Dr. Hans Keirstead
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
1, IMM01-STEM
When you expect your next catalyst update?
Phase 1/2a STEM-MYO clinical trial readout and preliminary Phase 2 STEM-clinical trial readout
What is your next catalyst (value inflection) update?
Jan 2026
Primary Speaker
.png)
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}